Skip to content

BioVie Inc.: 10-Q filed 2025-05-12

What BioVie Inc. reported in its quarterly report filed 2025-05-12 (fiscal Q3 2025): 37 published measures, 111 facts as tagged in accession 0001520138-25-000144.

This filing

Form
10-Q (quarterly report)
Filed
2025-05-12
Fiscal period
fiscal Q3 2025
Accession
0001520138-25-000144 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioVie Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-03-3124,660,215USD
At 2024-06-3025,208,345USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-03-312,842,270USD
At 2024-06-309,702,130USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-03-3121,817,945USD
At 2024-12-3123,922,579USD
At 2024-09-3014,067,085USD
At 2024-06-3015,506,215USD
At 2024-03-3118,925,927USD
At 2023-12-317,491,235USD
At 2023-09-307,547,928USD
At 2023-06-3015,340,286USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-03-3123,152,014USD
At 2024-06-3023,843,798USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,788,418USD90
2024-10-01 to 2024-12-31-7,112,529USD92
2024-07-01 to 2024-09-30-4,152,032USD92
2024-01-01 to 2024-03-31-8,067,830USD91
2023-10-01 to 2023-12-31-8,401,445USD92
2023-07-01 to 2023-09-30-10,710,464USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-13,417,738USD274
2023-07-01 to 2024-03-31-23,938,485USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2025-03-3112,725,954USD274
2023-07-01 to 2024-03-3120,302,939USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-07-01 to 2024-03-3114,525,000USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-03-31-348,655,105USD
At 2024-06-30-334,232,661USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-03-3118,507,218shares90
2024-07-01 to 2025-03-3113,503,512shares274
2024-01-01 to 2024-03-314,480,108shares91
2023-07-01 to 2024-03-313,986,991shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-03-3118,507,218shares90
2024-07-01 to 2025-03-3113,503,512shares274
2024-01-01 to 2024-03-314,480,108shares91
2023-07-01 to 2024-03-313,986,991shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-0.15USD/shares90
2024-07-01 to 2025-03-31-1.07USD/shares274
2024-01-01 to 2024-03-31-2USD/shares91
2023-07-01 to 2024-03-31-7.04USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-0.15USD/shares90
2024-07-01 to 2025-03-31-1.07USD/shares274
2024-01-01 to 2024-03-31-2USD/shares91
2023-07-01 to 2024-03-31-7.04USD/shares275

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-07-01 to 2025-03-31842,638USD274
2023-07-01 to 2024-03-312,118,649USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,988,204USD90
2024-07-01 to 2025-03-31-14,403,115USD274
2024-01-01 to 2024-03-31-7,732,055USD91
2023-07-01 to 2024-03-31-27,389,285USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-03-3123,721,541USD
At 2024-06-3024,048,190USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-03-312,546,553USD
At 2024-06-309,352,236USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-03-312,475,840USD
At 2024-06-303,586,912USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2025-03-31345,711USD
At 2024-06-30345,711USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-03-31235,685USD
At 2024-06-30407,718USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-03-312,988,204USD90
2024-07-01 to 2025-03-3114,403,115USD274
2024-01-01 to 2024-03-317,732,055USD91
2023-07-01 to 2024-03-3127,389,285USD275

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,585,869USD90
2024-07-01 to 2025-03-316,188,703USD274
2024-01-01 to 2024-03-311,974,264USD91
2023-07-01 to 2024-03-316,170,883USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,344,991USD90
2024-07-01 to 2025-03-318,042,379USD274
2024-01-01 to 2024-03-315,700,447USD91
2023-07-01 to 2024-03-3121,046,369USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-03-3118,517,376shares
At 2024-06-306,190,072shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-03-3123,152,014USD
At 2024-06-3023,843,798USD
At 2024-03-3130,350,337USD
At 2023-06-3019,460,883USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-03-31357,278USD
At 2024-06-30406,726USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-03-31366,430USD
At 2024-06-30410,237USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-03-31235,685USD
At 2024-06-30407,718USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-03-31569,527USD
At 2024-06-30204,392USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,788,418USD90
2024-07-01 to 2025-03-31-14,052,979USD274
2024-01-01 to 2024-03-31-8,067,830USD91
2023-07-01 to 2024-03-31-27,179,739USD275

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,788,418USD90
2024-07-01 to 2025-03-31-14,422,444USD274
2024-01-01 to 2024-03-31-8,954,253USD91
2023-07-01 to 2024-03-31-28,242,753USD275

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-01-01 to 2025-03-3157,344USD90
2024-07-01 to 2025-03-31172,033USD274
2024-01-01 to 2024-03-3157,344USD91
2023-07-01 to 2024-03-31172,033USD275

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-01-01 to 2025-03-314,998USD90
2024-07-01 to 2025-03-31327,722USD274
2024-01-01 to 2024-03-31628,711USD91
2023-07-01 to 2024-03-312,453,979USD275

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-01-01 to 2025-03-31199,786USD90
2024-07-01 to 2025-03-31350,136USD274
2024-01-01 to 2024-03-31-335,775USD91
2023-07-01 to 2024-03-31209,546USD275

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-07-01 to 2025-03-31178,932USD274
2023-07-01 to 2024-03-311,293,419USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-07-01 to 2025-03-3115,674,613USD274
2023-07-01 to 2024-03-3127,802,939USD275

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-1,111,072USD274
2023-07-01 to 2024-03-31933,495USD275

Inspect the source

Entity
BioVie Inc. / CIK 0001580149
Captured
2026-09-20T09:22:31.582Z
SEC response SHA-256
f572a001c48a2e876d70fd7a358ae1e5a994eab357401042d4f8aa6551a9ee85

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001580149.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))